Superior Planning, LLC’s Palvella Therapeutics PVLA Stock Holding History

Superior Planning, LLC’s Portfolio PVLA Stock Details PVLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$1.24K	Buy	+9	New	+$1.33K	﹤0.01%	1706

Other funds holding PVLA

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $71.4B AUM 33.43% 1-Year Est. Return

Invesco Atlanta, Georgia $1.27T AUM 50.62% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Emerald Advisers Leola, Pennsylvania $3.64B AUM 71.19% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $4.23B AUM 121.47% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.8B AUM 33.92% 1-Year Est. Return

Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.45B AUM 70.46% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Superior Planning, LLC's PVLA Position: Q3 2026 in Review

Superior Planning, LLC opened a new position in Palvella Therapeutics (PVLA) in Q3 2026: 9 shares worth $1.24K. The stake represents ﹤0.01% of the portfolio and ranks #1706 among its holdings.

109 funds tracked by Wall St. Rank hold PVLA as of Q3 2026.

Superior Planning, LLC held 9 shares of Palvella Therapeutics worth $1.24K as of Q3 2026.
Palvella Therapeutics was a new Superior Planning, LLC position in Q3 2026.
Palvella Therapeutics made up ﹤0.01% of Superior Planning, LLC's portfolio in Q3 2026, its #1706 holding.
109 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q3 2026.

Based on Superior Planning, LLC's 13F filing for Q3 2026, filed 12 Nov 2026.